# A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

> **NCT06083207** · PHASE1,PHASE2 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 116 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** IBI3003

## Key facts

- **NCT ID:** NCT06083207
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-29
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06083207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06083207, "A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06083207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*